Innate Pharma SA (NASDAQ:IPHA) Q1 2023 Earnings Conference Call May 10, 2023 8:00 AM ET
Company Participants
Henry Wheeler - VP, IR & Communication
Mondher Mahjoubi - Chairman & CEO
Joyson Karakunnel - EVP & Chief Medical Officer
Yannis Morel - EVP, Product Portfolio Strategy & Business Development
Frederic Lombard - SVP & CFO
Conference Call Participants
Ashiq Mubarack - Citigroup
Daina Graybosch - SVB Securities
Swayampakula Ramakanth - H.C. Wainwright & Co.
Justine Telliez - Kepler Cheuvreux
Jingming Chen - Evercore ISI
Operator
Thank you for joining the Innate Pharma Publication of Revenue for First Quarter 2023 Conference Call. [Operator Instructions].
Without further ado, I am pleased to introduce Henry Wheeler, Vice President, Investor Relations and Communications. Henry, over to you.
Henry Wheeler
Thank you. Good morning, good afternoon, and welcome, everyone. This morning, Innate issued a press release providing a business update for Q1 2023. We look forward to highlighting the progress made during the year to-date as well as addressing future goals and milestones. The press release and today's presentation are both available on the IR section of our website.
On Slide 2, before we start, I'd like to remind you that we will make forward-looking statements regarding the financial outlook in addition to regulatory and product plan development. These statements are subject to risks and uncertainties that may cause actual results to differ from those forecasted.
On Slide 3, for today's call, we will be joined by Mondher Mahjoubi, our Chief Executive Officer, who will then hand over to Joyson Karakunnel, our Chief Medical Officer, who will cover updates on lacutamab and monolizumab. Yannis Morel, Head of BD and Product Portfolio Strategy will then cover some anchor updates on BD, who will then hand over to Mondher for close. We will also have our CFO, Frederic Lombard, on the line for questions. Mondher, I'll now hand over to you.
Mondher Mahjoubi
Thank you, Henry. Good morning, good afternoon, everyone, and welcome to this call. Let's maybe move to Slide 4 first to remind everyone what is our strategy. As you know, we are early clinical-stage company. Our business model centers around 3 key priorities where we look to drive value from our early R&D efforts to a later stage partnership, where it makes sense to do so.
Our ambition is to develop innovative drug candidates that contribute to transform cancer care through a very strong pipeline of differentiated antibodies. So first, we look to create near-term value, driven by our lead proprietary asset, lacutamab, which is in development for T-cell lymphoma, with final cutaneous T-cell lymphoma readouts expected to happen in the second half of this year. Early peripheral T-cell lymphoma data are underway.